Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders

E. Jost, N. do Ó, E. Dahl, C. E. Maintz, P. Jousten, L. Habets, S. Wilop, J. G. Herman, R. Osieka, O. Galm

Research output: Contribution to journalArticle

Abstract

An acquired autoactivating mutation with a V617F amino-acid substitution in the JAK2 tyrosine kinase is frequently found in BCR/ABL-negative myeloproliferative disorders (MPD). Hypermethylation of CpG islands within gene promoter regions is associated with transcriptional inactivation and represents an important mechanism of gene silencing in the pathogenesis of hematopoietic malignancies. In this study, we determined the DNA methylation status of 13 cancer-related genes in the context of JAK2 mutations in 39 patients with MPD. Genes analyzed for hypermethylation were SOCS-1, SHP-1, E-cadherin, MGMT, TIMP-2, TIMP-3, p15, p16, p73, DAPK1, RASSF1A, RARβ2 and hMLH1. We found at least one hypermethylated gene in 15/39 MPD patient specimens, and in 6/39 samples aberrant methylation of the negative cytokine regulator SOCS-1 was present. The JAK2V617F mutation was found in 21/39 patients as determined by allele-specific polymerase chain reaction. Hypermethylation of SOCS-1 was observed in 3/21 patients with an autoactivating JAK2 mutation and in 3/18 patients with wild-type JAK2. Our results suggest that epigenetic inactivation of SOCS-1 may be a complementary mechanism to the JAK2V617F mutation in the pathogenesis of MPD that leads to dysregulation of JAK-STAT signal transduction and thus contributes to growth factor hypersensitivity.

Original languageEnglish (US)
Pages (from-to)505-510
Number of pages6
JournalLeukemia
Volume21
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Myeloproliferative Disorders
Epigenomics
Protein-Tyrosine Kinases
Mutation
Tissue Inhibitor of Metalloproteinase-3
Genes
Tissue Inhibitor of Metalloproteinase-2
CpG Islands
Neoplasm Genes
Gene Silencing
Hematologic Neoplasms
DNA Methylation
Amino Acid Substitution
Cadherins
Genetic Promoter Regions
Methylation
Signal Transduction
Intercellular Signaling Peptides and Proteins
Hypersensitivity
Alleles

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. / Jost, E.; do Ó, N.; Dahl, E.; Maintz, C. E.; Jousten, P.; Habets, L.; Wilop, S.; Herman, J. G.; Osieka, R.; Galm, O.

In: Leukemia, Vol. 21, No. 3, 03.2007, p. 505-510.

Research output: Contribution to journalArticle

Jost, E, do Ó, N, Dahl, E, Maintz, CE, Jousten, P, Habets, L, Wilop, S, Herman, JG, Osieka, R & Galm, O 2007, 'Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders', Leukemia, vol. 21, no. 3, pp. 505-510. https://doi.org/10.1038/sj.leu.2404513
Jost, E. ; do Ó, N. ; Dahl, E. ; Maintz, C. E. ; Jousten, P. ; Habets, L. ; Wilop, S. ; Herman, J. G. ; Osieka, R. ; Galm, O. / Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. In: Leukemia. 2007 ; Vol. 21, No. 3. pp. 505-510.
@article{50496e547708419483cf7cdaa8d9c435,
title = "Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders",
abstract = "An acquired autoactivating mutation with a V617F amino-acid substitution in the JAK2 tyrosine kinase is frequently found in BCR/ABL-negative myeloproliferative disorders (MPD). Hypermethylation of CpG islands within gene promoter regions is associated with transcriptional inactivation and represents an important mechanism of gene silencing in the pathogenesis of hematopoietic malignancies. In this study, we determined the DNA methylation status of 13 cancer-related genes in the context of JAK2 mutations in 39 patients with MPD. Genes analyzed for hypermethylation were SOCS-1, SHP-1, E-cadherin, MGMT, TIMP-2, TIMP-3, p15, p16, p73, DAPK1, RASSF1A, RARβ2 and hMLH1. We found at least one hypermethylated gene in 15/39 MPD patient specimens, and in 6/39 samples aberrant methylation of the negative cytokine regulator SOCS-1 was present. The JAK2V617F mutation was found in 21/39 patients as determined by allele-specific polymerase chain reaction. Hypermethylation of SOCS-1 was observed in 3/21 patients with an autoactivating JAK2 mutation and in 3/18 patients with wild-type JAK2. Our results suggest that epigenetic inactivation of SOCS-1 may be a complementary mechanism to the JAK2V617F mutation in the pathogenesis of MPD that leads to dysregulation of JAK-STAT signal transduction and thus contributes to growth factor hypersensitivity.",
author = "E. Jost and {do {\'O}}, N. and E. Dahl and Maintz, {C. E.} and P. Jousten and L. Habets and S. Wilop and Herman, {J. G.} and R. Osieka and O. Galm",
year = "2007",
month = "3",
doi = "10.1038/sj.leu.2404513",
language = "English (US)",
volume = "21",
pages = "505--510",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders

AU - Jost, E.

AU - do Ó, N.

AU - Dahl, E.

AU - Maintz, C. E.

AU - Jousten, P.

AU - Habets, L.

AU - Wilop, S.

AU - Herman, J. G.

AU - Osieka, R.

AU - Galm, O.

PY - 2007/3

Y1 - 2007/3

N2 - An acquired autoactivating mutation with a V617F amino-acid substitution in the JAK2 tyrosine kinase is frequently found in BCR/ABL-negative myeloproliferative disorders (MPD). Hypermethylation of CpG islands within gene promoter regions is associated with transcriptional inactivation and represents an important mechanism of gene silencing in the pathogenesis of hematopoietic malignancies. In this study, we determined the DNA methylation status of 13 cancer-related genes in the context of JAK2 mutations in 39 patients with MPD. Genes analyzed for hypermethylation were SOCS-1, SHP-1, E-cadherin, MGMT, TIMP-2, TIMP-3, p15, p16, p73, DAPK1, RASSF1A, RARβ2 and hMLH1. We found at least one hypermethylated gene in 15/39 MPD patient specimens, and in 6/39 samples aberrant methylation of the negative cytokine regulator SOCS-1 was present. The JAK2V617F mutation was found in 21/39 patients as determined by allele-specific polymerase chain reaction. Hypermethylation of SOCS-1 was observed in 3/21 patients with an autoactivating JAK2 mutation and in 3/18 patients with wild-type JAK2. Our results suggest that epigenetic inactivation of SOCS-1 may be a complementary mechanism to the JAK2V617F mutation in the pathogenesis of MPD that leads to dysregulation of JAK-STAT signal transduction and thus contributes to growth factor hypersensitivity.

AB - An acquired autoactivating mutation with a V617F amino-acid substitution in the JAK2 tyrosine kinase is frequently found in BCR/ABL-negative myeloproliferative disorders (MPD). Hypermethylation of CpG islands within gene promoter regions is associated with transcriptional inactivation and represents an important mechanism of gene silencing in the pathogenesis of hematopoietic malignancies. In this study, we determined the DNA methylation status of 13 cancer-related genes in the context of JAK2 mutations in 39 patients with MPD. Genes analyzed for hypermethylation were SOCS-1, SHP-1, E-cadherin, MGMT, TIMP-2, TIMP-3, p15, p16, p73, DAPK1, RASSF1A, RARβ2 and hMLH1. We found at least one hypermethylated gene in 15/39 MPD patient specimens, and in 6/39 samples aberrant methylation of the negative cytokine regulator SOCS-1 was present. The JAK2V617F mutation was found in 21/39 patients as determined by allele-specific polymerase chain reaction. Hypermethylation of SOCS-1 was observed in 3/21 patients with an autoactivating JAK2 mutation and in 3/18 patients with wild-type JAK2. Our results suggest that epigenetic inactivation of SOCS-1 may be a complementary mechanism to the JAK2V617F mutation in the pathogenesis of MPD that leads to dysregulation of JAK-STAT signal transduction and thus contributes to growth factor hypersensitivity.

UR - http://www.scopus.com/inward/record.url?scp=33847223121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847223121&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404513

DO - 10.1038/sj.leu.2404513

M3 - Article

C2 - 17230231

AN - SCOPUS:33847223121

VL - 21

SP - 505

EP - 510

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -